{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:45:48Z","timestamp":1788486348887,"version":"build-2803163510"},"reference-count":71,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NACO"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3934\/naco.2025025","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:27:27Z","timestamp":1757928447000},"page":"116-145","source":"Crossref","is-referenced-by-count":1,"title":["A novel machine-learning based optimization: identifying new treatment regimens for tuberculosis"],"prefix":"10.3934","volume":"18","author":[{"given":"Maral","family":"Budak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pariksheet","family":"Nanda","sequence":"additional","affiliation":[{"name":"Dept. of Microbiology and Immunology, University of Michigan Medical School, 48109-5620, Ann Arbor, MI, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Dept. of Microbiology and Immunology, University of Michigan Medical School, 48109-5620, Ann Arbor, MI, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2321","reference":[{"key":"key-10.3934\/naco.2025025-1","unstructured":"

D. Abraham, Boost C++ Library, 1998.<\/p>"},{"key":"key-10.3934\/naco.2025025-2","doi-asserted-by":"crossref","unstructured":"

E. Agmon, R. K. Spangler and C. J. Skalnik, et al. Vivarium: an interface and engine for integrative multiscale modeling in computational biology, Bioinformatics<\/i>, 38<\/b> (2022), 1972-1979.<\/p>","DOI":"10.1093\/bioinformatics\/btac049"},{"key":"key-10.3934\/naco.2025025-3","doi-asserted-by":"publisher","DOI":"10.3389\/fsysb.2023.1188009"},{"key":"key-10.3934\/naco.2025025-4","doi-asserted-by":"crossref","unstructured":"

G. Bellu, M. P. Saccomani and S. Audoly, et al. DAISY: A new software tool to test global identifiability of biological and physiological systems, Comput. Methods Programs Biomed<\/i>, 88<\/b> (2007), 52-61.<\/p>","DOI":"10.1016\/j.cmpb.2007.07.002"},{"key":"key-10.3934\/naco.2025025-5","doi-asserted-by":"crossref","unstructured":"

D. R. Bergman, K. A. Norton and H. V. Jain, et al. Connecting agent-based models with high-dimensional parameter spaces to multidimensional data using SMoRe ParS: A surrogate modeling approach, Bull Math Biol, <\/i> 86<\/b> (2023), 11.<\/p>","DOI":"10.1007\/s11538-023-01240-6"},{"key":"key-10.3934\/naco.2025025-6","doi-asserted-by":"crossref","unstructured":"

M. J. Boeree, N. Heinrich and R. Aarnoutse, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial, Lancet Infect Dis., <\/i> 17<\/b> (2017), 39-49.<\/p>","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"key-10.3934\/naco.2025025-7","doi-asserted-by":"crossref","unstructured":"

M. Budak, J. M. Cicchese and P. Maiello, et al. Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens, PLOS Computational Biology<\/i>, 19<\/b> (2023), e1010823.<\/p>","DOI":"10.1371\/journal.pcbi.1010823"},{"key":"key-10.3934\/naco.2025025-8","doi-asserted-by":"crossref","unstructured":"

M. Budak, L. E. Via and D. M. Weiner, et al. A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approach, CPT Pharmacometrics Syst. Pharmacol, <\/i> 13<\/b> (2024), 673-685.<\/p>","DOI":"10.1002\/psp4.13117"},{"key":"key-10.3934\/naco.2025025-9","unstructured":"

S. Butler, D. Kirschner and S. Lenhart, Optimal Control of Chemotherapy Affecting the Infectivity of HIV, (1997), 557-569.<\/p>"},{"key":"key-10.3934\/naco.2025025-10","doi-asserted-by":"crossref","unstructured":"

J. M. Cicchese, V. Dartois and D. E. Kirschner, et al. Both pharmacokinetic variability and granuloma heterogeneity impact the ability of the first-line antibiotics to sterilize tuberculosis granulomas, Front. Pharmacol., <\/i> 11<\/b> (2020), 333<\/p>","DOI":"10.3389\/fphar.2020.00333"},{"key":"key-10.3934\/naco.2025025-11","doi-asserted-by":"crossref","unstructured":"

J. M. Cicchese, E. Pienaar and D. E. Kirschner, et al. Applying optimization algorithms to tuberculosis antibiotic treatment regimens, Cell Mol. Bioeng.<\/i>, 10<\/b> (2017), 523-535.<\/p>","DOI":"10.1007\/s12195-017-0507-6"},{"key":"key-10.3934\/naco.2025025-12","doi-asserted-by":"crossref","unstructured":"

J. M. Cicchese, A. Sambarey and D. Kirschner, et al. A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs, Sci. Rep.<\/i>, 11<\/b> (2021), 5643.<\/p>","DOI":"10.1038\/s41598-021-84827-0"},{"key":"key-10.3934\/naco.2025025-13","doi-asserted-by":"crossref","unstructured":"

N. A. Cilfone, C. R. Perry and D. E. Kirschner, et al. Multi-scale modeling predicts a balance of tumor necrosis factor-alpha and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection, PloS One, <\/i> 8<\/b> (2013), e68680.<\/p>","DOI":"10.1371\/journal.pone.0068680"},{"key":"key-10.3934\/naco.2025025-14","doi-asserted-by":"crossref","unstructured":"

F. Conradie, T. R. Bagdasaryan and S. Borisov et al., Bedaquiline-pretomanid- linezolid regimens for drug-resistant tuberculosis, N. Engl. J. Med., <\/i> 387<\/b> (2022), 810-823.<\/p>","DOI":"10.1056\/NEJMoa2119430"},{"key":"key-10.3934\/naco.2025025-15","doi-asserted-by":"crossref","unstructured":"

A. H. Diacon, R. Dawson, F. von Groote-Bidlingmaier et al., 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial, Lancet, <\/i> 380<\/b> (2012), 986-993.<\/p>","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"key-10.3934\/naco.2025025-16","doi-asserted-by":"crossref","unstructured":"

A. H. Diacon, R. F. Patientia and A. Venter, et al., Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears, Antimicrob. Agents Chemother, <\/i> 51<\/b> (2007), 2994-2996.<\/p>","DOI":"10.1128\/AAC.01474-06"},{"key":"key-10.3934\/naco.2025025-17","doi-asserted-by":"crossref","unstructured":"

S. E. Dorman, J. L. Johnson and S. Goldberg, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis, Am. J. Respir. Crit. Care. Med., <\/i> 180<\/b> (2009), 273-280.<\/p>","DOI":"10.1164\/rccm.200901-0078OC"},{"key":"key-10.3934\/naco.2025025-18","doi-asserted-by":"crossref","unstructured":"

S. E. Dorman, P. Nahid and E. V. Kurbatova, et al., Four-month rifapentine regimens with or without moxifloxacin for tuberculosis, N. Engl. J. Med., <\/i> 384<\/b> (2021), 1705-1718.<\/p>","DOI":"10.1056\/NEJMoa2033400"},{"key":"key-10.3934\/naco.2025025-19","doi-asserted-by":"crossref","unstructured":"

M. Fallahi-Sichani, M. El-Kebir and S. Marino, et al., Multiscale computational modeling reveals a critical role for TNF-alpha receptor 1 dynamics in tuberculosis granuloma formation, J. Immunol.<\/i> 186<\/b> (2011), 3472-3483.<\/p>","DOI":"10.4049\/jimmunol.1003299"},{"key":"key-10.3934\/naco.2025025-20","doi-asserted-by":"crossref","unstructured":"

L. L. Fonseca, L. Bottcher and B. Mehrad, et al., Optimal control of agent-based models via surrogate modeling, PLoS Comput. Biol.<\/i>, 21<\/b> (2025), e1012138.<\/p>","DOI":"10.1371\/journal.pcbi.1012138"},{"key":"key-10.3934\/naco.2025025-21","doi-asserted-by":"crossref","unstructured":"

A. I. Forrester, A. S\u00f3bester and A. J. Keane, Engineering Design via Surrogate Modelling: A Practical Guide<\/i>, John Wiley & Sons, 2008.<\/p>","DOI":"10.1002\/9780470770801"},{"key":"key-10.3934\/naco.2025025-22","unstructured":"

M. Frigo and S. G. Johnson, Fastest Fourier Transform in the West(FFTW). 2003. url: https:\/\/www.fftw.org<\/ext-link>.<\/p>"},{"key":"key-10.3934\/naco.2025025-23","unstructured":"

M. Galassi, J. Theiler, B. Gough and G. Jungman, GNU Scientific Library, 2001. url: https:\/\/www.gnu.org\/software\/gsl\/<\/ext-link>.<\/p>"},{"key":"key-10.3934\/naco.2025025-24","doi-asserted-by":"crossref","unstructured":"

H. P. Gideon, J. Phuah, B. A. Junecko, et al., Neutrophils express pro- and anti-inflammatory cytokines in granulomas from Mycobacterium tuberculosis-infected cynomolgus macaques, Mucosal Immunol<\/i>, 12<\/b> (2019), 1370-1381.<\/p>","DOI":"10.1038\/s41385-019-0195-8"},{"key":"key-10.3934\/naco.2025025-25","doi-asserted-by":"crossref","unstructured":"

S. H. Gillespie, A. M. Crook, T. D. McHugh, et al., Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis, N. Engl. J. Med., <\/i> 371<\/b> (2014), 1577-1587.<\/p>","DOI":"10.1056\/NEJMoa1407426"},{"key":"key-10.3934\/naco.2025025-26","unstructured":"

Global Tuberculosis Report 2024, Geneva, World Health Organization, 2024, url: https:\/\/iris.who.int\/handle\/10665\/379339<\/ext-link>.<\/p>"},{"key":"key-10.3934\/naco.2025025-27","doi-asserted-by":"crossref","unstructured":"

A. Jindani, T. S. Harrison and A. J. Nunn, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis, N. Engl. J. Med., <\/i> 371<\/b>(2014), 1599-1608.<\/p>","DOI":"10.1056\/NEJMoa1314210"},{"key":"key-10.3934\/naco.2025025-28","doi-asserted-by":"crossref","unstructured":"

L. Joslyn, D. Kirschner and J. Linderman, CaliPro: A calibration protocol that utilizes parameter density estimation to explore parameter space and calibrate complex biological models, Cellular and Molecular Bioengineering<\/i>, 31-47.<\/p>","DOI":"10.1007\/s12195-020-00650-z"},{"key":"key-10.3934\/naco.2025025-29","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01586-16"},{"key":"key-10.3934\/naco.2025025-30","doi-asserted-by":"crossref","unstructured":"

D. Kirschner, C. A. Hunt and S. Marino, et al., Tuneable resolution as a systems biology approach for multi-scale, multi-compartment computational models, Wiley Interdiscip Rev. Syst. Biol. Med., <\/i> 6<\/b> (2014), 289-309.<\/p>","DOI":"10.1002\/wsbm.1270"},{"key":"key-10.3934\/naco.2025025-31","doi-asserted-by":"publisher","DOI":"10.1007\/s002850050076"},{"key":"key-10.3934\/naco.2025025-32","unstructured":"

D. Kirschner and A. Perelson, A model for the immune system response to HIV: AZT treatment studies, in Mathematical Population Dynamics: Analysis of Hetergeneity and Theory of Epidemics<\/i> (eds. O. Arino, D. Axelrod, M. Kimmel and M. Langlais), Wuerz Publishing, 1995,295-310.<\/p>"},{"key":"key-10.3934\/naco.2025025-33","doi-asserted-by":"crossref","unstructured":"

J. Larkins-Ford, T. Greenstein and N. Van, et al., Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis, Cell Syst.<\/i> 12<\/b> (2021), 1046-1063.<\/p>","DOI":"10.1016\/j.cels.2021.08.004"},{"key":"key-10.3934\/naco.2025025-34","doi-asserted-by":"crossref","unstructured":"

T. S. Ligon, F. Frohlich and O. T. Chis, et al., GenSSI 2.0: multi-experiment structural identifiability analysis of SBML models, Bioinformatics, <\/i> 34<\/b> (2018), 1421-1423.<\/p>","DOI":"10.1093\/bioinformatics\/btx735"},{"key":"key-10.3934\/naco.2025025-35","doi-asserted-by":"crossref","unstructured":"

S. Y. Low, P. Eng and G. H. Keng, et al., Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis, Respirology, <\/i> 11<\/b> (2006), 84-89.<\/p>","DOI":"10.1111\/j.1440-1843.2006.00789.x"},{"key":"key-10.3934\/naco.2025025-36","doi-asserted-by":"crossref","unstructured":"

S. Ma, S. Jaipalli and J. Larkins-Ford, et al., Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against tuberculosis, mBio, <\/i> 10<\/b> (2019).<\/p>","DOI":"10.1128\/mBio.02627-19"},{"key":"key-10.3934\/naco.2025025-37","doi-asserted-by":"crossref","unstructured":"

S. Marino, I. B. Hogue and C. J. Ray, et al., A methodology for performing global uncertainty and sensitivity analysis in systems biology, J. Theor. Biol.<\/i> 254<\/b> (2008), 178-196.<\/p>","DOI":"10.1016\/j.jtbi.2008.04.011"},{"key":"key-10.3934\/naco.2025025-38","doi-asserted-by":"crossref","unstructured":"

C. J. Martin, A. M. Cadena and V. W. Leung, et al., Digitally barcoding mycobacterium tuberculosis reveals in vivo infection dynamics in the macaque model of tuberculosis, mBio, <\/i> 8<\/b> (2017).<\/p>","DOI":"10.1128\/mBio.00312-17"},{"key":"key-10.3934\/naco.2025025-39","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-015-0098-0"},{"key":"key-10.3934\/naco.2025025-40","doi-asserted-by":"crossref","unstructured":"

P. Nahid, S. E. Dorman and N. Alipanah, et al. Executive summary: Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis, Clin. Infect. Dis.<\/i> 63<\/b> (2016), 853-867.<\/p>","DOI":"10.1093\/cid\/ciw566"},{"key":"key-10.3934\/naco.2025025-41","doi-asserted-by":"crossref","unstructured":"

P. Nanda, M. Budak and C. T. Michael, et al., Development and analysis of multiscale models for tuberculosis: From molecules to populations, Predicting Pandemics in a Globally Connected World, <\/i> 2<\/b> (2024), 11-43.<\/p>","DOI":"10.1007\/978-3-031-56794-0_2"},{"key":"key-10.3934\/naco.2025025-42","doi-asserted-by":"publisher","DOI":"10.3389\/fams.2023.1256443"},{"key":"key-10.3934\/naco.2025025-43","doi-asserted-by":"crossref","unstructured":"

E. L. Nuermberger, T. Yoshimatsu and S. Tyagi, et al., Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis, Am. J. Respir. Crit. Care. Med., <\/i> 169<\/b> (2004), 421-426.<\/p>","DOI":"10.1164\/rccm.200310-1380OC"},{"key":"key-10.3934\/naco.2025025-44","doi-asserted-by":"crossref","unstructured":"

E. L. Nuermberger, T. Yoshimatsu and S. Tyagi, et al., Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis, Am. J. Respir. Crit. Care. Med., <\/i> 170<\/b> (2004), 1131-1134.<\/p>","DOI":"10.1164\/rccm.200407-885OC"},{"key":"key-10.3934\/naco.2025025-45","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldh047"},{"key":"key-10.3934\/naco.2025025-46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01567-09"},{"key":"key-10.3934\/naco.2025025-47","doi-asserted-by":"publisher","DOI":"10.1016\/0025-5564(93)90043-A"},{"key":"key-10.3934\/naco.2025025-48","doi-asserted-by":"crossref","unstructured":"

E. Pienaar, N. A. Cilfone and P. L. Lin, et al., A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment, Journal of Theoretical Biology, <\/i> 367<\/b> (2015), 166-179.<\/p>","DOI":"10.1016\/j.jtbi.2014.11.021"},{"key":"key-10.3934\/naco.2025025-49","doi-asserted-by":"crossref","unstructured":"

E. Pienaar, V. Dartois and J. J. Linderman, et al., In silico evaluation and exploration of antibiotic tuberculosis treatment regimens, BMC Syst. Biol., <\/i> 9<\/b> (2015), 79.<\/p>","DOI":"10.1186\/s12918-015-0221-8"},{"key":"key-10.3934\/naco.2025025-50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196322"},{"key":"key-10.3934\/naco.2025025-51","doi-asserted-by":"crossref","unstructured":"

E. Pienaar, J. Sarathy and B. Prideaux, et al., Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach, PLoS Comput. Biol., <\/i> 13<\/b> (2017), e1005650.<\/p>","DOI":"10.1371\/journal.pcbi.1005650"},{"key":"key-10.3934\/naco.2025025-52","unstructured":"

Qt. 1995, url: https:\/\/www.qt.io<\/ext-link>.<\/p>"},{"key":"key-10.3934\/naco.2025025-53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802297"},{"key":"key-10.3934\/naco.2025025-54","doi-asserted-by":"crossref","unstructured":"

D. Rifat, B. Prideaux and R. M. Savic, et al., Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data, Sci. Transl. Med., <\/i> 10<\/b> (2018).<\/p>","DOI":"10.1126\/scitranslmed.aai7786"},{"key":"key-10.3934\/naco.2025025-55","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00159-19"},{"key":"key-10.3934\/naco.2025025-56","doi-asserted-by":"crossref","unstructured":"

J. P. Sarathy, L. E. Via and D. Weiner, et al., Extreme drug tolerance of mycobacterium tuberculosis in caseum, Antimicrob Agents Chemother, <\/i> 62<\/b> (2018).<\/p>","DOI":"10.1128\/AAC.02266-17"},{"key":"key-10.3934\/naco.2025025-57","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.29.454327"},{"key":"key-10.3934\/naco.2025025-58","doi-asserted-by":"crossref","unstructured":"

Y. Sch\u00e4lte, E. Klinger and E. Alamoudi, et al., pyABC: Efficient and robust easy- to-use approximate Bayesian computation, Journal of Open Source Software, <\/i> (2022), 7.<\/p>","DOI":"10.21105\/joss.04304"},{"key":"key-10.3934\/naco.2025025-59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2004.06.031"},{"key":"key-10.3934\/naco.2025025-60","unstructured":"

Aylin Sertkaya, Anna Birkenbach, Ayesha Berlind and John Eyraud, Examination of Clinical Trial Costs and Barriers for Drug Development. Tech. Rep., HHSP23337007T. U.S. Department of Health and Human Services, July 2014.<\/p>"},{"key":"key-10.3934\/naco.2025025-61","doi-asserted-by":"crossref","unstructured":"

S. P. Sethi, What Is Optimal Control Theory?<\/i> Optimal Control Theory<\/i>, Springer, Cham., 2021, 1-23.<\/p>","DOI":"10.1007\/978-3-030-91745-6_1"},{"key":"key-10.3934\/naco.2025025-62","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-024-01294-0"},{"key":"key-10.3934\/naco.2025025-63","doi-asserted-by":"crossref","unstructured":"

A. S\u00f3bester, Alexander I. J. Forrester, David J. J. Toal, Es Tresidder and Simon Tucker, Engineering design applications of surrogate-assisted optimization techniques, Optimization and Engineering, 15<\/b> (2014), 243\u2013265.<\/p>","DOI":"10.1007\/s11081-012-9199-x"},{"key":"key-10.3934\/naco.2025025-64","doi-asserted-by":"crossref","unstructured":"

X. Song, P. Smith and R. Kalyanam, et al., Anvil - system architecture and experiences from deployment and early user operations, Practice and Experience in Advanced Research Computing, <\/i> (2022), 1-9.<\/p>","DOI":"10.1145\/3491418.3530766"},{"key":"key-10.3934\/naco.2025025-65","doi-asserted-by":"crossref","unstructured":"

H. Stass, A. Dalhoff and D. Kubitza, et al., Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects, Antimicrob Agents Chemother, <\/i> 42<\/b> (1998), 2060-2065.<\/p>","DOI":"10.1128\/AAC.42.8.2060"},{"key":"key-10.3934\/naco.2025025-66","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2013.0505"},{"key":"key-10.3934\/naco.2025025-67","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2019.0043"},{"key":"key-10.3934\/naco.2025025-68","doi-asserted-by":"crossref","unstructured":"

S. Wasserman, J. C. M. Brust and M. T. Abdelwahab, et al., Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study, J. Antimicrob Chemother, <\/i> 77<\/b> (2022), 1146-1154.<\/p>","DOI":"10.1093\/jac\/dkac019"},{"key":"key-10.3934\/naco.2025025-69","doi-asserted-by":"crossref","unstructured":"

G. Werutsky, B. Hochhegger and J. A. Lopes de Figueiredo Pinto, et al., PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114), BMC Cancer, <\/i> 19<\/b> (2019), 5.<\/p>","DOI":"10.1186\/s12885-018-5233-5"},{"key":"key-10.3934\/naco.2025025-70","doi-asserted-by":"crossref","unstructured":"

J. Xu, S. Y. Li and D. V. Almeida, et al., Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis, Antimicrob. Agents Chemother, <\/i> 63<\/b> (2019).<\/p>","DOI":"10.1128\/AAC.00021-19"},{"key":"key-10.3934\/naco.2025025-71","doi-asserted-by":"crossref","unstructured":"

Y. Xu, J. Wu and S. Liao, et al., Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes, Ann. Clin. Microbiol. Antimicrob., <\/i> 16<\/b> (2017), 67.<\/p>","DOI":"10.1186\/s12941-017-0239-4"}],"container-title":["Numerical Algebra, Control and Optimization"],"original-title":[],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:42:29Z","timestamp":1776840149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aimsciences.org\/\/article\/doi\/10.3934\/naco.2025025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":71,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3934\/naco.2025025","relation":{},"ISSN":["2155-3289","2155-3297"],"issn-type":[{"value":"2155-3289","type":"print"},{"value":"2155-3297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}